Bone-Marrow-Derived Mononuclear Cells Relieve Neuropathic Pain after Spinal Nerve Injury in Mice

Hiroshi Takamura,1,2 Tomoya Terashima,1 Kanji Mori,2 Miwako Katagi,1 Junko Okano,3 Yoshihisa Suzuki,3 Shinji Imai,2 and Hideto Kojima1

1Department of Stem Cell Biology and Regenerative Medicine, Shiga University of Medical Science, Shiga 520-2192, Japan; 2Department of Orthopedic Surgery, Shiga University of Medical Science, Shiga, Japan; 3Department of Plastic and Reconstructive Surgery, Shiga University of Medical Science, Shiga, Japan

Treating neuropathic pain is a critical clinical issue. Although numerous therapies have been proposed, effective treatments have not been established. Therefore, safe and feasible treatment methods are urgently needed. In this study, we investigated the therapeutic effects of autologous intrathecal administration of bone-marrow-derived mononuclear cells (MNCs) on neuropathic pain. We generated a mouse model of neuropathic pain by transecting the spinal nerve and evaluated neuropathic pain by measuring the mechanical threshold in the following 14 days. Mice in the MNC injection group had a higher mechanical threshold than those in the buffer group. We assessed the effect of MNC treatment on the dorsal root ganglia and spinal cord by immunohistochemistry, mRNA expression, and cytokine assay. The migration and accumulation of microglia were significantly suppressed in the MNC group, and the mRNA expression of inflammatory cytokines such as interleukin (IL)-6, IL-1β, and tumor necrosis factor alpha (TNF-α) was markedly downregulated. Furthermore, MNC administration tended to suppress various cytokines in the cerebrospinal fluid of the model mice. In conclusion, our results suggest that intrathecal injection of MNCs relieves neuropathic pain and might be a promising cell therapy for the treatment of this condition.

INTRODUCTION

Neuropathic pain is one of the most frequent uncontrollable diseases in daily medical care,1–5 with a prevalence ratio of approximately 1%–7% in the general population.1 This condition is primarily caused by mechanical compressive stimulation or inflammation of nerve roots due to spinal nerve damage, such as intervertebral disc herniation or nerve root extraction injury.1,4–6 Nerve injuries induce hyperalgesia and allodynia, which are representative symptoms of neuropathic pain.7,8

There are various therapeutic approaches to treat patients with neuropathic pain: physiological therapy, including exercise, electronic stimulation, and rehabilitation; drug therapy, such as anti-inflammatory analgesics, cell excitation inhibitors, and nerve blocker injection with anesthetics; and surgical therapy.9–11 Different therapies have been selected in the clinical scene. However, satisfactory guidelines for the treatment of neuropathic pain are still lacking. Therefore, new and effective therapies are required.

Recently, it was demonstrated that the immune system is deeply involved in the pathogenesis of neuropathic pain.12 Immune cells such as the monocyte/macrophage lineage and microglia, as well as the cytokines produced by these cells, induce the activation of ion channels and the secretion of neurotransmitters related with neuropathic pain in the dorsal root ganglia (DRGs) and spinal cord.11–14 Inflammatory cytokines such as interleukin (IL)-6, IL-1β, and tumor necrosis factor alpha (TNF-α) were reported to be upregulated and mediate neuropathic pain in a model mouse.15–17

We previously tested different gene therapies and molecular targeting drugs for neuropathic pain, focusing on specific molecules such as TNF-α in animal models.16,17 However, inhibiting only one molecule resulted in limited effects because many cytokines are involved in the pathogenesis of neuropathic pain. In addition, there is a significant hurdle to ensure safety when viral vectors or molecular targeting drugs are employed in humans.18

We previously reported that intrathecal injection of autologous bone-marrow-derived mononuclear cells (MNCs) is a safe and effective treatment for spinal cord injury, and that it suppresses inflammatory cytokines.19 The technique of MNC isolation and administration had been previously established as a treatment for spinal cord injury.19–22 However, there were no reports about the effect of intrathecal injection of bone-marrow-derived MNCs on neuropathic pain. Therefore, in this study, we focused on this association. We treated neuropathic pain in a model mouse with bone-marrow-derived MNCs to observe the therapeutic effects and explore the possibility of a clinical application.

Received 4 February 2020; accepted 23 March 2020; https://doi.org/10.1016/j.omtm.2020.03.020.

Correspondence: Tomoya Terashima, Department of Stem Cell Biology and Regenerative Medicine, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga 520-2192, Japan.
E-mail: tom@belle.shiga-med.ac.jp
Induced by Spinal Nerve Transection

Figure 1. Effects of Bone-Marrow-Derived Mononuclear Cells for Neuropathic Pain

(A) Schematic representation of cell therapy for neuropathic pain. Spinal nerve transection (SNT) was performed on day 0 at the left side of the spinal nerve, and GFP-positive mononuclear cells (MNCs) were intrathecally administrated on day 1. The mechanical threshold for hyperalgesia was measured on the ipsilateral (Ipsi) and contralateral (Cont) sides in mice administered buffer or MNCs for 14 days after SNT. White circles show the Cont side of the MNC group, black circles show the Ipsi side of MNC group, white squares show the Cont side of the buffer group, and black squares show the Ipsi side of the buffer group (n = 20 for each group). An arrowhead indicates the time of MNC or buffer injection. Data are represented as the mean ± SE. *p < 0.01 as compared with the buffer Ipsi and MNC Ipsi group. GFP, green fluorescent protein.

RESULTS

Effects of Bone-Marrow-Derived MNCs on Neuropathic Pain Induced by Spinal Nerve Transection

The mouse model of neuropathic pain was generated by spinal nerve transection (SNT) on the left side of the spinal nerve at the level of the fourth lumbar (L4) and L5 vertebrae of the MNC-injected mice on day 14 (Figure 2). GFP-positive cells were not recognized in the spinal cord (Figure 2A), but in the L4 and L5 DRGs on the ipsilateral side (Figures 2B and 2C), MNCs mainly accumulated at the L5 DRGs, where the spinal nerve had been transected, and to a lesser extent, at the L4 DRGs in the ipsilateral side of MNC-injected mice (Figure 2D).

MNCs Suppressed Microglial Migration in Ipsilateral L5 DRGs after SNT

To better understand the mechanisms underlying the effect of MNC injection, we investigated the migration of microglia, which is intimately related to inflammation and injury, in the regions where GFP-positive cells were observed in MNC-injected mice (L4 and L5 DRGs). We performed immunohistochemistry of the microglia marker Iba1 in the ipsilateral side of L4 and L5 DRGs on MNC-injected and buffer-injected mice on day 7 (Figure 3). Many Iba1-positive cells were observed around the neurons of ipsilateral L4 and L5 DRG tissues of SNT mice (Figure 3A). Iba1-positive cells were markedly increased in the ipsilateral side when compared with the contralateral side (Figure S1).

For the quantitative evaluation of Iba1 staining, Iba1-positive cells were counted, and the intensity of the Iba1-positive area was quantitated in the images binarized by ImageJ (Figures 3A, right panels, 3B, and 3C). The number of Iba1-positive cells was significantly lower in the ipsilateral L5 DRGs of MNC-injected SNT mice than in the buffer-injected SNT mice (Figure 3B). The average intensity of the Iba1-positive area in the L5 DRGs was significantly lower in the MNC group than in the buffer group (Figure 3C). In contrast, there was no significant difference in the number of Iba1-positive cells and the intensity of the positive area in the L4 DRGs between the MNC and buffer groups (Figures 3B and 3C). These results showed that MNCs suppressed the migration of microglia induced by spinal nerve injury.

MNCs Suppressed the Expression of Inflammatory Cytokines in the Ipsilateral L5 DRGs after SNT

We evaluated the expression of several cytokines in the ipsilateral L5 DRGs of MNC-injected or buffer-injected SNT mice on day 7 to analyze the inflammatory process further. We performed quantitative
PCR (qPCR) of representative inflammatory cytokines, IL-6, IL-1β, and TNF-α (Figure 4). The expression levels of the three cytokines were significantly lower in the MNC group than in the buffer group (Figure 4). These results indicated that MNC injection inhibited the inflammation associated with microglial migration and nerve transection.

**MNCs Suppressed Microglial Migration and the Expression of Inflammatory Cytokines in the Spinal Cord after SNT**

Next, we evaluated microglial migration and the expression of inflammatory cytokines in the dorsal horn of the spinal cord, which is the nearest afferent tract from the spinal nerve and DRGs. Immunohistochemistry of Iba1 was performed in the spinal cord of MNC-injected and buffer-injected mice (Figure 5). Iba1-positive cells accumulated at the dorsal horn of the ipsilateral side in the spinal cord of both groups but were hardly observed at the contralateral side (Figure 5A).

The accumulation of Iba1-positive cells was significantly suppressed in the MNC group when compared with the buffer group (Figures 5A and 5B). We performed qPCR of IL-6, IL-1β, and TNF-α in the ipsilateral spinal cord of MNC-injected or buffer-injected SNT mice on day 7 (Figure 6). The expression levels of the three cytokines were significantly suppressed in the MNC group when compared with the buffer group (Figure 6). These results were consistent with those of the DRG tissue and suggested that MNCs affected microglial migration and suppressed inflammation in the spinal cord.

**Cytokine Expression in the Cerebrospinal Fluid after MNC Therapy for Neuropathic Pain**

To investigate the influence of MNC injection on the humoral factors associated with spinal nerve injury, we examined the protein expression profile of cytokines in the cerebrospinal fluid (CSF) of MNC-injected and buffer-injected SNT mice by ELISA. We measured 32 cytokines, 25 of which were detectable in the spinal cord of both groups (Figure 7). The comparison analysis found that 8 cytokines were increased (Figure 7, red bars), 15 were decreased (Figure 7, blue bars), and 2 were unchanged (Figure 7) in the MNC group when compared with the buffer group. Interestingly, the eight cytokines that increased after MNC injection showed a less than 2-fold elevation. In contrast, 4 cytokines among the 15 that decreased showed a reduction of over 2-fold (Figure 7). Overall, MNC injection tended to suppress cytokine expression.

**DISCUSSION**

This study showed that intrathecal injection of bone-marrow-derived MNCs improved the mechanical threshold and suppressed neuropathic pain in mice with spinal nerve injury. MNCs mainly accumulated in the L5 DRGs and not in the spinal cord of treated mice. However, microglia accumulation and inflammatory cytokine expression were significantly suppressed in the DRGs and spinal cord after MNC injection. Therefore, MNCs not only affected the DRGs directly and the spinal cord indirectly.

In previous reports, MNCs showed therapeutic effects by suppressing several cytokines in rodent models of spinal cord injury and stroke.17,20,23,24 Humoral factors that originated from MNCs probably provided these therapeutic effects. Our study also indicated the involvement of non-cell direct effects, which is consistent with previous studies.17,20,23,24 MNC injection therapy has the potential to affect...
different tissues, cells, and the environment around injuries by suppressing several cytokines in neuronal tissues. In this study, MNC therapy caused partial pain remission for 14 days, and the therapeutic effect tended to diminish slightly by day 14. Thus, MNCs in ipsilateral L5 DRGs are expected to decrease after 14 days or more. However, changes in administrative strategies, such as increasing cell number or injection frequency, could result in a higher effect. Therefore, MNC injection therapy might provide a breakthrough in the treatment of intractable neuropathic pain.

Immune cells such as the monocyte/macrophage lineage and microglia have been reported to play a crucial role in inflammation-induced neuropathic pain and its pathogenesis. SNT induces the secretion of inflammatory cytokines, such as TNF-α, IL-1β, IL-6, and interferon regulatory factor (IRF) 5, which increase neuronal excitability and activate ATPases and voltage-gated sodium and calcium channels in the sensory nervous system. The studies above considered inflammatory cytokines as potential treatment targets for neuropathic pain.

We have tested and reported the results of anti-TNF-α drugs and gene therapies as treatments for neuropathic pain. In this study, bone-marrow-derived MNC administration was superior to treatments that target a specific molecule because it suppressed many cytokines. Our strategy represents an advantage over the use of artificial vectors or chemicals for gene delivery because it preserves the physiological conditions and can be administrated autologously, which could minimize the side effects and ensure the safety of this molecular therapy.

Other cell therapies, such as mesenchymal stem cells (MSCs), have been frequently used for the treatment of neuropathic pain. Intrathecal injection of MSCs showed therapeutic effects against neuropathic pain in previous studies. MSCs have the potential to differentiate into multiple cell types, including endothelial, bone, muscle, and lipid cells, which gives them an advantage in terms of repair and regenerative ability. Previous studies showed that MSCs improved synaptic transmission and neuronal networks, and had anti-proliferation, anti-inflammation, and anti-apoptosis effects, which helped to treat neuropathic pain. However, dealing with MSCs requires a cell sorting and cell processing center. In contrast, bone-marrow-derived MNCs can be collected through a simple and short procedure. MNCs could be administered to neuropathic pain patients in the clinical scene without the need for expensive facilities.
The application route of cell therapies is one of the most important points to consider. Various animal and clinical studies on the application of MNCs have been conducted. MNCs have been administrated into mouse disease models through several routes, such as intravenous, intramuscular, and intrathecal injection. The appropriate route depends on the therapeutic target tissues. Therapies for neuropathic pain should target nervous tissues, including the spinal cord, DRGs, peripheral nerves, and nociceptors. In the study, we targeted the DRGs and spinal cord because the spinal nerve was transected. Therefore, we selected intrathecal injection as our application route. Our results showed that the injected MNCs could directly access the DRGs through the CSF.

The safety of the administration method must be taken into account in clinical applications. Intravenous injection is a minimally invasive procedure for cell administration. However, it has systemic effects and may affect non-desired organs. Intrathecal injection is a local administration method, limited to the intrathecal space, which has minimal side effects. Some studies even reported no side effects. Lumbar puncture is often performed in the clinical practice, and is a safe and effective administration method that has been used for drug injection to treat neuropathic pain. In our study, intrathecal administration was performed for MNC injection and showed its effect without major side effects of motor sensory function. No mice died until day 14 after SNT and cell therapy.

MNCs have been used to treat different diseases in clinical and animal studies. MNC therapy has been reported to be effective for arteriosclerosis obliterans, Buerger disease, cerebral infarction, and spinal cord injury because of trophic effects, angiogenesis, and neurogenesis. We are currently performing a clinical trial of intrathecal MNC administration for spinal cord injury, and preliminary results showed therapeutic effects. Therefore, the safety of intrathecal administration of MNCs has been recognized and seems to be a feasible treatment for neuropathic pain, although we should confirm the effectiveness and its effective duration in clinical study. Here, we showed for the first time that intrathecal administration of MNCs relieved neuropathic pain caused by SNT by suppressing inflammatory cytokines in the DRGs and spinal cord. Autologous intrathecal administration of MNCs might be a promising cell therapy for the treatment of neuropathic pain.

MATERIALS AND METHODS

Ethics Statement

All experimental animal protocols were approved by the Institutional Animal Care and Usage Committee at Shiga University of Medical Science. All procedures were performed in accordance with the guidelines of the Research Center for Animal Life Science of Shiga University of Medical Science.

Animals

Male 8- to 9-week-old C57BL6 mice (SLC, Shizuoka, Japan) weighing 19.0–22.0 g were used in this study. C57BL/6-Tg (UBC-GFP) mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). The mice were housed in separated cages and maintained under a 12-h light and dark cycle. Food and tap water were available ad libitum.

Surgical Procedures

A neuropathic pain model by L5 SNT was generated following a previously described procedure. Mice were anesthetized by intraperitoneal administration of sodium pentobarbital (5 mg/kg). After a midline incision of the mouse back skin, the bilateral L5 transverse processes of the lumbar spine was removed. We exposed the bilateral L5 spinal nerves. Only the left side of the spinal nerve was transected at the distal to the L5 DRGs; the right spinal nerve was exposed without transection to serve as a negative control. After confirmation of hemostasis, the spine was restored, and the subcutaneous tissue and skin were sutured. The next day, mechanical hyperalgesia was confirmed.

Behavioral Test

Mechanical hyperalgesia was evaluated before the surgery and 1, 3, 5, 7, 10, and 14 days after SNT with a dynamic plantar aesthesiometer (Ugo Basile, Gemonio, Italy) as described previously. We calculated the mRNA expression of IL-6, IL-1β, and TNF-α in the L5 DRGs on day 7 after SNT and injection of bone-marrow-derived MNCs (n = 10 for each group). Data were standardized by β-actin mRNA expression. p < 0.05. Bars represent the mean ± SE.
evaluated to compare the ratio against the pressure in the contralateral side on day 0.

**Isolation and Injection of MNCs**

Total bone marrow cells were isolated from a GFP Tg mouse, and MNCs were isolated from bone marrow cells using a Ficoll-Paque (GE Healthcare, Chicago, IL, USA). Total bone marrow cells were mixed in 3 mL phosphate-buffered saline (PBS) and carefully layered upon 3 mL of Ficoll separation medium. Ficoll gradients were centrifuged for 30 min at 20°C and 400 x g (brake was turned off). The layer of whole MNCs was collected with a sterile pipette, washed with PBS, mixed with trypan blue, and counted by hemocytometer. The concentration was adjusted for injection. For the treatment of neuropathic pain, a midline incision of the skin was made at the lumbar region of the back side in day 1 SNT mice under deep anesthesia. After exposure of spine, 1 x 10^6 MNCs/10 μL were intrathecally injected using a Hamilton syringe with a 30G needle at intervertebral space of lumbar level. We confirmed by the evoked tail flick in mice whether the tip of the needle inserted into the subarachnoid space. PBS (10 μL) was injected into the buffer control group. Buffer and whole MNCs were intrathecally injected over approximately 2 min.

**mRNA Expression Analysis**

The spinal cord and DRGs were extracted from mice under deep anesthesia and immediately frozen in liquid nitrogen. Total RNA was extracted from frozen tissues with the RNeasy mini kit (QIAGEN, Hilden, Germany) with DNase I (RNase-free DNase set; QIAGEN) treatment. Reverse transcription was performed from 100 ng of total RNA in each tube using the PrimeScript RT reagent Kit with gDNA Eraser (Perfect Real Time; Takara Bio, Kusatsu, Japan). The quantitative real-time PCR assay was performed using a LightCycler 480 with SYBR Green (Roche Diagnostics, Manheim, Germany) according to a manufacturer’s protocol. The following primers were used: IL-6, forward, 5'-ACGGCCTTCCCTACTTCACA-3' and IL-6 reverse, 5'-CAATTTCAGGATTTCCCAGA-3'; IL-1β forward, 5'-CAACCAACAGTGATATTCTCCATG-3' and IL-1β reverse, 5'-GATCCACACTCTCAGTGCA-3'; TNF-α forward, 5'-CACCGTGCTGACAAA CCACAAAGTG-3' and TNF-α reverse, 5'-GATAGCCAAATCGGCTGACGTTGAGG-3'; β-actin forward, 5'-CGTGGGTGACCATC AAAGAGA-3' and β-actin reverse, 5'-TGGATGCCACAGAGTC CAT-3’. The normalization and the relative expression analysis of target genes were performed using the comparative cycle threshold method with β-actin as a control.

**Histological Analysis**

Animals were deeply anesthetized by intraperitoneal administration of 0.3 mg/kg medetomidine, 4.0 mg/kg midazolam, and 5.0 mg/kg butorphanol, and perfused with PBS followed by a fixative containing 4% paraformaldehyde in 0.1 M phosphate buffer. After perfusion fixation, animal tissues were kept in the same fixative at 4°C overnight. The fixative was replaced with 15% sucrose buffer the next day. The DRGs and spinal cord were isolated, embedded in Optimal Cutting Temperature compound (Tissue Tek, Sakura, Tokyo, Japan), frozen with liquid nitrogen, and cut to 10-μm sections on a cryostat. After mounting the sections in Vectashield medium with 4' 6-diamino-2-phenylindole (DAPI; Vector, Burlingame, CA, USA), GFP-positive cells were counted under a Leica TCS SP8 X confocal microscope with the Leica Application Suite X software (Leica, Tokyo, Japan). For immunohistochemical analysis, other sections were
blocked with 3% normal goat serum in PBS at room temperature for 30 min. Anti-Iba1 antibody (1:1,000; Abcam, Cambridge, UK) and Alexa Fluor 555 antibody (1:1,000; Abcam) were used as primary and secondary antibodies, respectively. The sections were mounted in Vectashield medium with DAPI (Vector). Fluorescence images were observed under a Leica TCS SP8 X confocal microscope with the Leica Application Suite X software (Leica). To evaluate all the sections, we prepared at least three consecutive sections (each of 30-μm intervals) and evaluated at least three scenes in each section. GFP-positive cells were counted in a 100 μm × 100 μm visual field in the spinal cord and the L4 and L5 DRGs of each group, and Iba1-positive cells were counted in the L4 and L5 DRGs. For the quantification of the intensity of Iba1-positive staining, red color in the images was isolated, converted to black-white binary images, and measured the intensity by ImageJ 1.52a (National Institutes of Health, Bethesda, MD, USA).

**Cytokine Assay in CSF**

CSF was collected from cistern magna at day 7 after SNT. Under deep anesthesia, a midline incision of the skin was made from occipital to neck region. After exposure of the dura mater, CSF was collected by a 30G needle. CSF was combined from three mice in the buffer or MNC groups. At least 15 μL of CSF was harvested from each mouse. The 32-cytokine assay in CSF was outsourced to GeneticLab (Sapporo, Japan). CSF was used for a multiplex assay running, and the concentration of 32 cytokines was measured with a Milliplex MAP kit HCYTMAG-70K-PX32 (Millipore, Burlington, MA, USA) and a Luminex 200 System (Luminex, Austin, TX, USA) by ELISA technology. The procedure was done according to the assay protocols and guidelines provided by Millipore. The cytokines included in the kit were as follows: G-CSF (granulocyte-colony-stimulating factor), Eotaxin, GM-CSF (granulocyte macrophage-colony-stimulating factor), IFN-γ (interferon-γ), IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12p40, IL-12p70, LIF (leukemia inhibitory factor), IL-13, LIX (keratinocyte-derived chemokines), IL-15, IL-17, IP-10 (interferon-γ-induced protein-10), KC (keratinocyte-derived chemokines), MCP-1 (monocyte chemoattractant protein-1), MIP-1α (macrophage inflammatory protein-1α), MIP-1β, M-CSF (macrophage-colony-stimulating factor), MIP-2, MIG (monokine induced by INF-γ), RANTES, TNF-α, and VEGF (vascular endothelial growth factor). The results were calculated by MasterPlex software (Hitachi Solutions America, Irvine, CA, USA).

**Statistical Analysis**

All data are expressed as the means + or ± standard error (SE). One-way ANOVA, followed by Tukey’s test was used to calculate the statistical significance for multiple datasets. For behavioral analyses, two-way ANOVA and Scheffe’s tests were used. A p value below 0.05 was considered significant.

**SUPPLEMENTAL INFORMATION**

Supplemental Information can be found online at https://doi.org/10.1016/j.omtm.2020.03.020.
AUTHOR CONTRIBUTIONS
H.T. conducted the experiments, analyzed the data, and wrote the manuscript. T.T. advised on the experimental procedures, designed the study, and helped to write and revise the manuscript. H.K., S.I., J.O., M.K., and K.M. advised on the experimental design and techniques, and provided expertise and feedback. All authors have read and approved the final manuscript.

CONFLICTS OF INTEREST
The authors declare no competing interests.

ACKNOWLEDGMENTS
We would like to thank the investigators at the Central Research Laboratory Shiga University of Medical Science for their technical support.

REFERENCES
1. Woods, B.I., and Hilibrand, A.S. (2015). Cervical radiculopathy: epidemiology, etiology, diagnosis, and treatment. J. Spinal Disord. Tech. 28, E251–E259.
2. Gilron, I., Baron, R., and Jensen, T. (2015). Neuropathic pain: principles of diagnosis and treatment. Mayo Clin. Proc. 90, 532–545.
3. Bouhassira, D., Lantéri-Minet, M., Attal, N., Laurent, B., and Touboul, C. (2008). Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 136, 380–387.
4. Deyo, R.A., and Mirza, S.K. (2016). CLINICAL PRACTICE. Herniated lumbar intervertebral disk. N. Engl. J. Med. 374, 1763–1772.
5. Ciaramitari, P., Padula, L., Devigili, G., Rota, E., Tamburin, S., Eleopra, R., Crucu, G., and Truini, A.; Neuropathic pain special interest group of the Italian Neurological Society (2017). Prevalence of neuropathic pain in patients with traumatic brachial plexus injury: A multicenter prospective hospital-based study. Pain Med. 18, 2428–2432.
6. Ciaramitari, P., Monedelli, M., Logollo, F., Grimaldi, S., Battiston, R., Sard, A., Scarinci, C., Migliaretti, G., Fascani, G., and Cocito, D.; Italian Network for Traumatic Neuropathies (2010). Traumatic peripheral nerve injuries: epidemiological findings, neuropathic pain and quality of life in 158 patients. J. Peripher. Nerv. Syst. 15, 120–127.
7. Xie, W.R., Deng, H., Li, H., Bowen, T.L., Strong, J.A., and Zhang, J.M. (2006). Robust increase of cutaneous sensitivity, cytokine production and sympathetic sprouting in rats with localized inflammatory irritation of the spinal ganglia. Neuroscience 142, 809–822.
8. Bradesi, S. (2010). Role of spinal cord glia in the central processing of peripheral pain perception. Neurogastroenterol. Motil. 22, 499–511.
9. Haslam, C., and Nurmikko, T. (2008). Pharmacological treatment of neuropathic pain in older persons. Clin. Interv. Aging 3, 111–120.
10. Stacey, B.R. (2005). Management of peripheral neuropathic pain. Am. J. Phys. Med. Rehabil. 84 (Suppl 3), S4–S16.
11. Scholz, J., and Wooff, C.J. (2007). The neuropathic pain triad: neurons, immune cells and glia. Nat. Neurosci. 10, 1361–1368.
12. Bennett, G.J. (1999). Does a neuroimmune interaction contribute to the genesis of painful peripheral neuropathies? Proc. Natl. Acad. Sci. USA 96, 7737–7738.
13. Marchand, F., Perretti, M., and McMahon, S.B. (2005). Role of the immune system in chronic pain. Nat. Rev. Neurosci. 6, 521–532.
14. Albrecht, D.S., Ahmed, S.U., Kettner, N.W., Borra, R.J.H., Cohen-Adad, J., Deng, H., Houle, T.T., Opalacz, A., Roth, S.A., Melo, M.F.V., et al. (2018). Neuroinflammation of the spinal cord and nerve roots in chronic radicular pain patients. Pain 159, 968–977.
15. Hung, A.L., Lim, M., and Doshi, T.L. (2017). Targeting cytokines for treatment of neuropathic pain. Scand. J. Pain 17, 287–293.
16. Ogawa, N., Kawai, H., Terashima, T., Kojima, H., Oka, K., Chan, L., and Maegawa, H. (2014). Gene therapy for neuropathic pain by silencing of TNF-α expression with lentiviral vectors targeting the dorsal root ganglion in mice. PLoS ONE 9, e92073.
17. Yamakawa, I., Kojima, H., Terashima, T., Katagi, M., Oi, J., Urabe, H., Sanada, M., Kawai, H., Chan, L., Yasuda, H., et al. (2011). Inactivation of TNF-α ameliorates diabetic neuropathy in mice. Am. J. Physiol. Endocrinol. Metab. 301, E844–E852.
18. Verma, I.M., and Somia, N. (1997). Gene therapy—promises, problems and prospects. Nature 389, 239–242.
19. Yoshifuru, T., Ohta, M., Tokuzawa, Y., Muramatsu, N., Desawa, M., Suzuki, Y., Yoshida, A., Watanabe, Y., Adachi, Y., Ikeda, S., et al. (2007). Neurorprotective effect of bone marrow-derived mononuclear cells promoting functional recovery from spinal cord injury. J. Neurotrauma 24, 1026–1036.
20. Tamura, K., Harada, Y., Nagashima, N., Itosi, T., Ishino, H., Yogo, T., Nenu, Y., Hara, Y., Suzuki, Y., Ide, C., and Tagawa, M. (2012). Autotransplantation of bone marrow–derived mononuclear cells for complete cases of canine paraplegia and loss of pain perception, secondary to intervertebral disc herniation. Exp. Clin. Transplant. 10, 263–272.
21. Kumar, A.A., Kumar, S.R., Narayanan, R., Arul, K., and Baskaran, M. (2009). Autologous bone marrow derived mononuclear cell therapy for spinal cord injury: A phase II/I clinical safety and primary efficacy data. Exp. Clin. Transplant. 7, 241–248.
22. Sharma, A., Gokulchandran, N., Chopra, G., Kulkarni, P., Lohia, M., Badhe, P., and Jacob, V.C. (2012). Administration of autologous bone marrow–derived mononuclear cells in children with incurable neurological disorders and injury is safe and improves their quality of life. Cell Transplant. 21 (Suppl 1), S79–S90.
23. Arai, K., Harada, Y., Tomiyama, H., Michishita, M., Kanno, N., Yogo, T., Suzuki, Y., and Hara, Y. (2016). Evaluation of the survival of bone marrow–derived mononuclear cells and the growth factors produced upon intrathecal immunotherapy in rat models of acute spinal cord injury. Res. Vet. Sci. 107, 88–94.
24. Yang, B., Migliati, E., Parsha, K., Schaak, K., Xi, X., Aronowski, J., and Savitz, S.I. (2013). Intra-arterial delivery is not superior to intravenous delivery of autologous bone marrow mononuclear cells in acute ischemic stroke. Stroke 44, 3463–3472.
25. Terashima, T., Ogawa, N., Nakae, Y., Sato, T., Katagi, M., Okano, J., Maegawa, H., and Kojima, H. (2018). Gene Therapy for Neuropathic Pain through sRNA-IRF5 Gene Delivery with Homer Peptides to Microglia. Mol. Ther. Nucleic Acids 11, 203–215.
26. Wilson-Gerwing, T.D., Stucky, C.L., McComb, G.W., and Verge, V.M.K. (2008). Neurotrophin-3 significantly reduces sodium channel expression linked to neuropathic pain states. Exp. Neurol. 213, 303–314.
27. Ogawa, N., Terashima, T., Oka, K., Chan, L., and Kojima, H. (2018). Gene therapy for neuropathic pain using dorsal root ganglion-targeted helper-dependent adenoviral vectors with GAD67 expression. Pain Res. Rep. 3, 695.
28. Hossein, M., Yousef, F., Axenid, H., and Nasratinad, F. (2015). The effect of bone marrow–derived mesenchymal stem cell transplantation on allograft and hypografts in neuropathic animals: a systematic review with meta-analysis. Biol. Blood Marrow Transplant. 21, 1537–1544.
29. Ogawa, N., Terashima, T., Oka, K., Chan, L., and Kojima, H. (2018). Gene therapy for neuropathic pain using dorsal root ganglion–targeted helper–dependent adenoviral vectors with GAD67 expression. Pain Res. Rep. 3, 695.
cell therapy in patients with peripheral arterial disease. J. Atheroscler. Thromb. 21, 1183–1196.

34. Savitz, S.I., Misra, V., Kasam, M., Juneja, H., Cox, C.S., Jr., Alderman, S., Aisiku, I., Kar, S., Gee, A., and Grotta, J.C. (2011). Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann. Neurol. 70, 59–69.

35. Tateishi-Yuyama, E., Matsubara, H., Murohara, T., Ikeda, U., Shintani, S., Masaki, H., Amano, K., Kishimoto, Y., Yoshimoto, K., Akashi, H., et al.; Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. (2002). Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 360, 427–435.

36. Motukuru, V., Suresh, K.R., Vivekanand, V., Raj, S., and Girija, K.R. (2008). Therapeutic angiogenesis in Buerger’s disease (thromboangiitis obliterans) patients with critical limb ischemia by autologous transplantation of bone marrow mononuclear cells. J. Vasc. Surg. 48 (Suppl 6), S53–S60, discussion S60.

37. Naruse, K., Sato, J., Funakubo, M., Hata, M., Nakamura, N., Kobayashi, Y., Kamiya, H., Shibata, T., Kondo, M., Himeo, T., et al. (2011). Transplantation of bone marrow-derived mononuclear cells improves mechanical hyperalgesia, cold allodynia and nerve function in diabetic neuropathy. PLoS ONE 6, e27458.

38. Boltze, J., Arnold, A., Walczak, P., Jolkkonen, J., Cui, L., and Wagner, D.C. (2015). The dark side of the force—constraints and complications of cell therapies for stroke. Front. Neurol. 6, 155.

39. Bakshi, A., Barshinger, A.L., Swanger, S.A., Madhavani, V., Shumsky, J.S., Neuhuber, B., and Fischer, I. (2006). Lumbar puncture delivery of bone marrow stromal cells in spinal cord contusion: a novel method for minimally invasive cell transplantation. J. Neurotrauma 23, 55–65.

40. Cao, J., Li, Z., Zhang, Z., Ren, X., Zhao, Q., Shao, J., Li, M., Wang, J., Huang, P., and Zang, W. (2014). Intrathecal injection of fluorocitric acid inhibits the activation of glial cells causing reduced mirror pain in rats. BMC Anesthesiol. 14, 119.

41. Sun, Y.E., Peng, L., Sun, X., Bo, J., Yang, D., Zheng, Y., Liu, C., Zhu, B., Ma, Z., and Gu, X. (2012). Intrathecal injection of spironolactone attenuates radicular pain by inhibition of spinal microglia activation in a rat model. PLoS ONE 7, e39897.

42. Cheng, K.L., Lai, C.S., Wang, F.Y., Wang, H.C., Chang, L.L., Ho, S.T., Tsai, H.P., and Kwan, A.L. (2011). Intrathecal lidocaine pretreatment attenuates immediate neurogenic pain by modulating Nav1.3 expression and decreasing spinal microglial activation. BMC Neurol. 11, 71.

43. Nakano-Doi, A., Nakagomi, T., Fujikawa, M., Nakagomi, N., Kubo, S., Lu, S., Yoshikawa, H., Soma, T., Taguchi, A., and Matsuyma, T. (2010). Bone marrow mononuclear cells promote proliferation of endogenous neural stem cells through vascular niches after cerebral infarction. Stem Cells 28, 1292–1302.

44. Kamihata, H., Matsubara, H., Nishinou, T., Fujiyama, S., Tsutsumi, Y., Ozono, R., Masaki, H., Mori, Y., Iba, O., Tateishi, E., et al. (2001). Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angio blasts, angiogenic ligands, and cytokines. Circulation 104, 1046–1052.

45. Nakayama, T., Nagata, E., Masuda, H., Asahara, T., and Takizawa, S. (2019). Regeneration-associated cell transplantation contributes to tissue recovery in mice with acute ischemic stroke. PLoS ONE 14, e0210198.

46. Li, Y., Dorsi, M.J., Meyer, R.A., and Belzberg, A.J. (2000). Mechanical hyperalgesia after an L5 spinal nerve lesion in the rat is not dependent on input from injured nerve fibers. Pain 85, 493–502.

47. Njoo, C., Heinl, C., and Kuner, R. (2014). In vivo SiRNA transfection and gene knockdown in spinal cord via rapid noninvasive lumbar intrathecal injections in mice. J. Vis. Exp. 85, e51229.

48. Terashima, T., Oka, K., Kritz, A.B., Kojima, H., Baker, A.H., and Chan, L. (2009). DRG-targeted helper-dependent adenoviruses mediate selective gene delivery for therapeutic rescue of sensory neuronopathies in mice. J. Clin. Invest. 119, 2100–2112.